



AerovectRx Corporation Receives \$250,000 Georgia Research Alliance VentureLab Phase III Award

Atlanta, Ga. – AerovectRx was recently awarded a Georgia Research Alliance Phase III VentureLab award of \$250,000 to commercialize AerovectRx's aerosol drug delivery technology.

GRA VentureLab is the signature commercialization program of the Georgia Research Alliance, a public/private partnership of Georgia's research universities, the business community and state government. Phase III awards (grants/loans up to \$250,000) are made to eligible GRA VentureLab companies that have fully executed licenses from the university or government agency and have Georgia-based management. GRA Eminent Scholar Ralph Tripp at the University of Georgia is assisting the company in testing its technology.

"The GRA is one of our greatest economic assets," says Dr. Tom Callaway, AerovectRx CEO. "Their programs are unsurpassed in helping Georgia's most promising start-ups commercially advance university and CDC-based research discoveries."

Founded in 2005, AerovectRx is an inhaled aerosol drug delivery company and the exclusive licensee of patented Centers for Disease Control and Prevention (CDC) technology originally developed for aerosolization of vaccines. AeroCELL™, AerovectRx's commercial adaptation of the CDC technology, is a simply operated, hand-held device that utilizes vibrating mesh technology to efficiently and reliably deliver small molecule drugs and complex biologics, including vaccines, to the respiratory tract.

"AerovectRx is an excellent example of the power of combining the ingenuity of CDC scientists with that of Georgia's university-based researchers," said Dr. Lee Herron, GRA Vice President of Commercialization. "We expect many other opportunities for collaborations like this one in the future."

About AerovectRx - Founded in 2005, AerovectRx is an inhaled aerosol drug delivery company and the exclusive licensee of patented Centers for Disease Control technology originally developed for aerosolization of vaccines. AeroCELL™, AerovectRx's commercial adaptation of the CDC technology, is a small, highly portable, simply operated, hand-held device, utilizing vibrating mesh technology that efficiently and reliably delivers small molecule drugs and complex biologics including vaccines, to the respiratory tract.

Media Contact:
Sara Gatlin
sgatlin@aerovectrx.com
404-920-2052